title: A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
abstract: Breast cancer is one of the most frequently diagnosed cancers and a leading cause of death in women worldwide. Despite significant advances in the treatment of hormone receptor-positive breast cancer, tumor metastasis occurs frequently and is associated with poor long-term prognosis. The mammalian target of rapamycin (mTOR) pathway plays a central role in cancer cell growth, proliferation, and resistance to endocrine therapies. Therefore, mTOR inhibitors such as everolimus in combination with nonsteroidal aromatase inhibitors might reverse endocrine resistance and improve clinical outcomes in patients. Here, we report on a case of infiltrating lobular carcinoma of the breast with metastases to the bone. Histopathologic analysis showed that the patient was estrogen and progesterone receptor positive and human epidermal growth factor-2 negative. This case represents the clinical spectrum of complications caused by metastasis: the patient experienced a considerable amount of skeletal-related complications, had previously received chemotherapy, and experienced disease progression while taking nonsteroidal aromatase inhibitors. After treatment with oral everolimus 10 mg daily plus oral exemestane 25 mg daily, the patient's disease was ameliorated. Combination therapy was well tolerated, with minimal adverse effects that were manageable with concomitant medications. Although further analyses in larger populations are necessary, the addition of everolimus to exemestane might provide an effective new treatment option for patients with bone metastasis.
authors.affiliation: Highlands Oncology Group, Fayetteville, Ark., USA.
authors.forename: J Thaddeus
authors.initials: JT
authors.lastname: Beck
authors.affiliation: Highlands Oncology Group, Fayetteville, Ark., USA.
authors.forename: Ryan
authors.initials: R
authors.lastname: Mantooth
keywords: Advanced breast cancer; Everolimus; Hormone receptor
references.citation: J Clin Invest. 2010 Jul;120(7):2406-13
references.pmid: 20530877
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: Adv Ther. 2013 Oct;30(10 ):870-84
references.pmid: 24158787
references.citation: Eur J Cancer. 2013 Aug;49(12 ):2621-32
references.pmid: 23735704
references.citation: FEBS Lett. 2010 Jan 4;584(1):124-8
references.pmid: 19925796
references.citation: J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):102-10
references.pmid: 17616457
references.citation: Curr Oncol Rep. 2013 Feb;15(1):14-23
references.pmid: 23054937
references.citation: J Natl Cancer Inst. 2013 May 1;105(9):654-63
references.pmid: 23425564
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Clin Oncol. 2012 Aug 1;30(22):2718-24
references.pmid: 22565002